Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0546 • ACR Convergence 2024
Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice
Nehad Soloman¹, Jawad Bilal² and John Tesser³, ¹Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, ²Arizona Arthritis & Rheumatology Associates, PC, Tucson, AZ, ³Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting 1.4% of the US adult population. The leading clinical symptom of axSpA is chronic inflammatory…
Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 1437 • ACR Convergence 2024
Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
Sze-Lok Lau¹, Huan Meng², Isaac Cheng¹, Bryan PY Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²The Faculty of Medicine, CUHK, Hong Kong, China (People's Republic), ³The Chinese University of Hong Kong, New Territories, Hong Kong
Background/Purpose: In patients with axial spondyloarthritis (AxSpA), we have reported that higher inflammatory burden as reflected by a longer disease duration, delay in diagnosis and…
Abstract Number: 1759 • ACR Convergence 2024
Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study
Denis Poddubnyy¹, Juergen Braun², Pedro M Machado³, Victoria Navarro Compán⁴, Lianne S Gensler⁵, Kay Geert Hermann⁶, Erhard Quebe-Fehling⁷, Christelle C Pieterse⁸, Aimee Readie⁹, Corine Gaillez⁷ and Xenofon Baraliakos¹⁰, ¹Charite-Universitatsmedizin Berlin, Berlin, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁴La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Charite Medical School, Berlin, Germany, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Syneos Health, Amsterdam, Netherlands, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Previous studies have identified predictors of radiographic spinal progression in patients with axial spondyloarthritis (axSpA). In this post hoc analysis of the SURPASS study…
Abstract Number: 2367 • ACR Convergence 2024
Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Philip Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Alexander Marten⁴, Ute Massow⁴, Vishvesh Shende³, Myriam Manente⁵, Luke Peterson⁶, Katy White³, Peter Nash⁷ and Lianne S Gensler⁸, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Charite-Universitatsmedizin Berlin, Berlin, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim am Rhein, Germany, ⁵UCB Pharma, Braine-l'Alleud, Belgium, ⁶UCB Pharma, Morrisville, NC, ⁷School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ was generally well tolerated by patients (pts)…
Abstract Number: 0550 • ACR Convergence 2024
Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study
Nelly Ziade¹, Ihsane Hmamouchi², Clementina López Medina³, Maroun Aoun⁴, Sherif Gamal⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²International University of Rabat, Rabat, Morocco, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Saint Joseph University, Beirut, Lebanon, ⁵Cairo University, Cairo, Egypt, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…
Abstract Number: 0819 • ACR Convergence 2024
The Assessment of SpondyloArthritis International Society (ASAS) Definition of Difficult-to-Manage Axial Spondyloarthritis
Denis Poddubnyy¹, Xenofon Baraliakos², Victoria Navarro Compán³, Murat Torgutalp⁴ and Desiree van der Heijde⁵, and ASAS Difficult-to-Manage Axial Spondyloarthritis Task Force, ¹Charite-Universitatsmedizin Berlin, Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁴Charite Universitatsmedizin - Berlin, Berlin, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Non-response to standard treatments represents a management challenge in axial Spondyloarthritis (axSpA). The Assessment of SpondyloArthritis international Society (ASAS) seeks to define 'difficult-to-manage axSpA'…
Abstract Number: 1440 • ACR Convergence 2024
Significant Indicators Identified for Carotid Doppler Ultrasound Use in Axial Spondyloarthritis Patients Without Conventional Cardiovascular Risk Factors
Brona Dinneen¹ and Finbar O'Shea², ¹St James's Hospital,, Dublin, Dublin, Ireland, ²St James's Hospital, Dublin, Dublin, Ireland
Background/Purpose: The EULAR cardiovascular screening recommendations advocate for the use of carotid dopplers in patients with inflammatory joint diseases to detect subclinical atherosclerosis. Despite these…
Abstract Number: 1760 • ACR Convergence 2024
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis
Walter Maksymowych¹, Robert Lambert¹, Paula Śliwinska-Stańczyk², Piotr Adrian Klimiuk³, Anusha Yeshokumar⁴, Elizabeth Cerullo⁴, Rebecca Kepich⁴, Chahin Pachai⁴ and Steven Greenberg⁴, ¹University of Alberta, Edmonton, AB, Canada, ²Centrum Medyczne ReumaPark, Warsaw, Poland, ³Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: CC-99677 (also known as BMS-986371) is a novel, orally bioavailable, small-molecule covalent inhibitor of mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MK2). The MK2…
Abstract Number: 0553 • ACR Convergence 2024
Analyzing the Utilization of HLA-B27 Testing in a Large Rural Health System: Implications for Diagnostic Appropriateness
Sanjeev Shrestha¹, Angela Bobak², Idorenyin Udoeyo³, Pradeep Puri⁴, Jordan Law⁵ and David Bulbin⁶, ¹Geisinger Medical Center, Bloomsburg, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center, Danville, PA, ⁴Geisinger Medical Center, Danville, ⁵Geisinger Health System, Danville, ⁶Geisinger Health System, Danville, PA
Background/Purpose: Human leukocyte antigen (HLA)-B27 is linked to spondyloarthropathies (SpA), uveitis, and inflammatory bowel disease (IBD). By analyzing ordering diagnoses and final diagnoses during patient…
Abstract Number: 0820 • ACR Convergence 2024
The Classification in Axial Spondyloarthritis Inception Cohort Study: Performance of the 2009 Assessments in Spondyloarthritis International Society Classification Criteria
Walter Maksymowych¹, Desiree van der Heijde², Liron Caplan³, Robert Landewé⁴, Lianne S Gensler⁵, Pedro M. Machado⁶, Alexandre Sepriano⁷, Floris van Gaalen⁸, Miranda van Lunteren⁹, Ben Vandermeer¹⁰, Joachim Sieper¹¹, Atul Deodhar¹² and Martin Rudwaleit¹³, and on behalf of CLASSIC Study investigators, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Amsterdam University Medical Center, Meerssen, Netherlands, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁷Leiden University Medical Centre, Portela Loures, Portugal, ⁸LUMC, Leiden, Zuid-Holland, Netherlands, ⁹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ¹⁰University of Alberta, Edmonton, Canada, ¹¹Charité University Medicine Berlin, Berlin, Germany, ¹²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ¹³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: The 2009 ASAS classification criteria had sensitivity of 83% and specificity of 84% for a rheumatologist diagnosis of axSpA. However, their implementation revealed varying…
Abstract Number: 1445 • ACR Convergence 2024
Systematic Characterization of MRI Lesions Per ASAS Definitions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Comparisons Among Subgroups with Psoriasis, Iritis, Colitis, AxSpA Alone, and Matched Back Pain Controls
Ulrich Weber¹, Susanne Pedersen², Ozun Bayindir Tsechelidis³, Robert Lambert⁴, Joel Paschke⁵, Stephanie Wichuk⁴ and Walter Maksymowych⁴, ¹Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ²Rigshospitalet, København, Denmark, ³Ottawa University, Ottawa, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: There is limited information on the frequency and topographical distribution of MRI lesions in the sacroiliac joints (SIJ) of patients with axSpA according to…
Abstract Number: 1837 • ACR Convergence 2024
Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment
Addison Pacheco¹, Zoya Qaiyum², Fataneh Tavasolian³, Melissa Lim⁴, Michael Tang¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto, ON, Canada, ³Krembil Research Institute - the University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR) in axial spondyloarthritis (axSpA) patients before biologic treatment.Methods: CD45RO+CD45RA-CD4+ T…
Abstract Number: 0554 • ACR Convergence 2024
Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
Carolina Merino¹, Zulema Plaza², Jordi Gratacos Masmitja³, Iago Rodríguez-Lago⁴, Elisa Trujillo⁵, Ignacio Marin-Jimenez⁶, Eva Perez Pampin⁷, Manuel Barreiro⁸, Vanesa Hernández-Hernández⁹, Marta Carrillo-Palau¹⁰, Maria Luz Garcia Vivar¹¹, Maria Carmen Muñoz¹², María Lourdes Ladehesa-Pineda¹³, Eva Iglesias Flores¹⁴, Yago González-Lama¹⁵, Marta Arevalo Salaet¹⁶, Xabier Calvet¹⁷, Ana Gutierrez-Casbas¹⁸ and JESUS SANZ SANZ¹⁹, and EISER group, ¹Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³University Hospital Parc Taulí, Sabadell, Spain, ⁴Gastroenterology department. Hospital Universitario Galdakao-Usansolo, Instituto de Investigación Sanitaria Biobizkaia, Galdakao, Bizkaia, Spain, Galdakao, Spain, ⁵Rheumatology department. Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ⁶Gastroenterology department. Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁷Rheumatology department. Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Santiago de Compostela, Spain, ⁸Gastroenterology department. Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁹Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, ¹⁰Gastroenterology department. Hospital Universitario Canarias, La Laguna, Spain., Santa Cruz de Tenerife, Spain, ¹¹Basurto Hospital, Bilbao, Spain, ¹²Gastroenterology department. Hospital Universitario Basurto Hospital Universitario Basurto. Bilbao. Spain., Bilbao., Spain, ¹³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁴Gastroenterology department. Hospital Reina Sofia, Córdoba, Spain, Cordoba, Spain, ¹⁵Servicio de Gastroenterología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Spain, ¹⁶Parc Tauli Hospital Universitari I3PT, Rheumatology, Medicine Department, UAB, Sabadell, Spain, ¹⁷Gastroenterology department. Parc Taulí, Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Sabadell, Spain, Sabadell, Spain, ¹⁸Gastroenterology department. Hospital General Universitario de Dr. Balmis de Alicante. ISABIAL y CIBERehd, Alicante, Spain, Alicante, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: Axial spondyloarthritis (AxSpA) encompasses both non-radiographic axial spondyloarthritis (nr-AxSpA) and radiographic axial spondyloarthritis (r-AxSpA), also known as ankylosing spondylitis (AS). Although nr-AxSpA is often…
Abstract Number: 0821 • ACR Convergence 2024
Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis
Susanne Pedersen¹, Ulrich Weber², Ozun Bayindir Tsechelidis³, Robert Lambert⁴, Joel Paschke⁵, Stephanie Wichuk⁴ and Walter Maksymowych⁴, ¹Rigshospitalet, København, Denmark, ²Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ³Ottawa University, Ottawa, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Recent analysis of MRI scans from the 2009 ASAS classification cohort has led to a new proposal for the application of more stringent MRI…

1
2
3
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.